الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 89 |  |  |
| | | from | 89 | | |
Abstract
Vascular endothelial growth factors have been extensively studied over the past few years. Ranibizumab is an antibody fragment that binds and inhibits all isoforms of VEGF.It is a 48-kDa humanized Fab fragment of a murine monoclonal anti-VEGF antibody. Specific development of ranibizumab for intraocular use was driven. Ranibizumab relatively long systemic half-life of full-length antibodies (versus antibody fragments).Ranibizumab differs from pegaptanib in that it is a humanized monoclonal antibody fragment against VEGF-A that binds all isoforms of the endogenous growth factor and its biologically active cleavage by-products.For patients with diabetic macular edema, VEGF inhibitors seemed to be more effective as a short-term treatment option than alternative therapies, however, the evidence is not of sufficient quality to confirm safety. While agents like bevacizumab and ranibizumab appear to be safe and effective.
In addition, it has been recorded that, serial injections of anti-VEGF agents might lead to persistent IOP elevations, whereas, the clinician should recognize this phenomenon, as it can occur even if the patient has tolerated multiple prior injections without IOP elevation. Prolonged monitoring of IOP might not be necessary on the day of injection in most cases, however, cautious monitoring should be considered in selected cases.
Our study was conducted to evaluate early changes in intraocular pressure following repeted intravitreal ranibizumab injections of 0.1ml (2.5 mg),50 eyes were scheduled for intravitreal ranibizumab 0.05 ml(1.25mg). We conclude that intra ocular pressure (IOP) rises after intraviteal ranibizumab is transient and returns to normal level after one day.